LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Codexis Inc

Gesloten

SectorGezondheidszorg

2.48 -2.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.44

Max

2.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-18M

-8.7M

Verkoop

-24M

15M

EPS

-0.1

Winstmarge

-57.083

Werknemers

146

EBITDA

-23M

-5.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+177.11% upside

Dividenden

By Dow Jones

Volgende Winsten

12 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.6M

232M

Vorige openingsprijs

4.84

Vorige sluitingsprijs

2.48

Nieuwssentiment

By Acuity

100%

0%

326 / 345 Rangschikking in Healthcare

Codexis Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 nov 2025, 21:37 UTC

Winsten

Codexis to Cut About 24% of Workforce

Peer Vergelijking

Prijswijziging

Codexis Inc Prognose

Koersdoel

By TipRanks

177.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.9 USD  177.11%

Hoogste 11 USD

Laagste 2 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Codexis Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Sentiment

By Acuity

326 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat